SUPN Q3 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$102M-0.8% YoY

Gross Profit

$97M95.3% margin

Operating Income

$40M38.9% margin

Net Income

$29M28.3% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$37M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$550M

Stockholders' Equity

$557M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102M	$103M	-0.8%
Gross Profit	$97M	$99M	-1.5%
Operating Income	$40M	$37M	+6.0%
Net Income	$29M	$28M	+3.0%

Revenue Segments

Product

$100M98%

Royalty

$2M2%